Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-017-0788-4) contains supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Baccarani, Michele, Rosti, Gianantonio, Cottone, Francesco, Cannella, Laura, Guilhot, François, Vignetti, Marco, Efficace, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464/
https://www.ncbi.nlm.nih.gov/pubmed/29047379
http://dx.doi.org/10.1186/s12955-017-0788-4
_version_ 1783272400317579264
author Breccia, Massimo
Baccarani, Michele
Rosti, Gianantonio
Cottone, Francesco
Cannella, Laura
Guilhot, François
Vignetti, Marco
Efficace, Fabio
author_facet Breccia, Massimo
Baccarani, Michele
Rosti, Gianantonio
Cottone, Francesco
Cannella, Laura
Guilhot, François
Vignetti, Marco
Efficace, Fabio
author_sort Breccia, Massimo
collection PubMed
description We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-017-0788-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5648464
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56484642017-10-26 Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients Breccia, Massimo Baccarani, Michele Rosti, Gianantonio Cottone, Francesco Cannella, Laura Guilhot, François Vignetti, Marco Efficace, Fabio Health Qual Life Outcomes Letter to the Editor We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-017-0788-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-18 /pmc/articles/PMC5648464/ /pubmed/29047379 http://dx.doi.org/10.1186/s12955-017-0788-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Breccia, Massimo
Baccarani, Michele
Rosti, Gianantonio
Cottone, Francesco
Cannella, Laura
Guilhot, François
Vignetti, Marco
Efficace, Fabio
Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title_full Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title_fullStr Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title_full_unstemmed Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title_short Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
title_sort physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648464/
https://www.ncbi.nlm.nih.gov/pubmed/29047379
http://dx.doi.org/10.1186/s12955-017-0788-4
work_keys_str_mv AT brecciamassimo physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT baccaranimichele physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT rostigianantonio physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT cottonefrancesco physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT cannellalaura physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT guilhotfrancois physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT vignettimarco physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients
AT efficacefabio physiciansattitudetowardsselectionofsecondlinetherapywithnilotinibanddasatinibinchronicmyeloidleukemiapatients

Ejemplares similares